var path='https://www.tickertech.net'; function heading(heading) { document.write('

'+ ''+ '
• '+heading+'
'+ ''+ '

'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('

\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
4/26 - 6:45 AM \; \;U.S. FDA Approves Pfizer\'s BEQVEZ™\; (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
4/25 - 1:45 PM \; \;Daily Dividend Report: PFE, SCHW, CI, MPC, AVY [VIDEO]
4/24 - 4:37 PM \; \;Pfizer Declares Second-Quarter 2024 Dividend
4/22 - 8:08 AM \; \;European Commission Approves Pfizer\'s EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options
4/17 - 12:39 PM \; \;Wednesday\'s ETF with Unusual Volume: IHE [VIDEO]
4/11 - 10:00 AM \; \;Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
4/9 - 6:45 AM \; \;Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO in Adults Aged 18 to 59 at Increased Risk for RSV Disease
4/8 - 12:46 PM \; \;ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
4/8 - 8:23 AM \; \;ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
4/5 - 12:13 PM \; \;Friday\'s ETF with Unusual Volume: PJP [VIDEO]
4/4 - 1:56 PM \; \;Thursday\'s ETF with Unusual Volume: IYH [VIDEO]
4/1 - 12:24 PM \; \;Monday\'s ETF with Unusual Volume: IYH [VIDEO]
3/21 - 12:18 PM \; \;Thursday\'s ETF with Unusual Volume: PPH [VIDEO]
3/20 - 10:00 AM \; \;Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
3/13 - 4:00 AM \; \;European Commission Approves Pfizer\'s PREVENAR 20 to Help Protect Infants and Children Against Pneumococcal Disease
3/12 - 6:45 AM \; \;Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS Regimen in Patients with Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL)
3/6 - 2:19 PM \; \;ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges
3/6 - 12:05 PM \; \;ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral Therapy in Individuals Living With HIV Who Have Adherence Challenges
3/5 - 10:00 AM \; \;Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
3/5 - 8:48 AM \; \;ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities
more news
\n'); } if (!allow) { document.write(''+ ''+ '

Access Denied

'+ '

Please Read This Important Message

'+ ' If you are a paying TickerTech.com client and your account was not set up to include the configuration'+ ' received, please email support@tickertech.com,'+ ' or call us at 1-866-515-2082 to verify your account settings.'+ ' '+ '

'+ ' '+ ' Note! If you reached this page'+ ' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+ ' paying client. For pricing information please visit our products page, email '+ ' services@tickertech.com, or give us a call at 1-866-515-2082.'+ ' '+ '

'+ ' '+ ' TickerTech.com home
'+ ' TickerTech.com products'+ '
'+ ' '+ ''); } }